- Home
- APLS vs COMP Comparison
APLS vs COMP Comparison
Compare APLS & COMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLS | COMP |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 6.1B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | APLS | COMP |
|---|---|---|
| Price | $41.05 | $8.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 10 |
| Target Price | ★ $33.59 | $11.80 |
| AVG Volume (30 Days) | 8.3M | ★ 12.7M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.50 | 67.74 |
| EPS | ★ 0.15 | 0.03 |
| Revenue | $1,003,782,000.00 | ★ $6,961,600,000.00 |
| Revenue This Year | N/A | $90.43 |
| Revenue Next Year | $18.19 | $8.63 |
| P/E Ratio | ★ $273.60 | $280.17 |
| Revenue Growth | ★ 28.46 | 23.67 |
| 52 Week Low | $16.61 | $5.70 |
| 52 Week High | $41.14 | $13.96 |
Technical Indicators
Market Signals| Indicator | APLS | COMP |
|---|---|---|
| Relative Strength Index (RSI) | 84.57 | 53.23 |
| Support Level | $19.29 | $7.35 |
| Resistance Level | $41.14 | $8.33 |
| Average True Range (ATR) | 0.06 | 0.50 |
| MACD | -0.65 | 0.03 |
| Stochastic Oscillator | 58.33 | 41.51 |
Price Performance
Historical ComparisonAbout APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
About COMP Compass Inc.
Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.